CAS: 53783-83-8; Tromantadine

上下游产品

1-氯乙酰氨基金刚烷 N-(1-Adamantyl)-2-Chloroacetamide 5689-59-8

📜N,N-二甲基乙醇胺,1-氯乙酰氨基金刚烷置于sodium Hydride体系中,用 四氢呋喃,Mineral Oil 作为反应溶剂,化学反应 3.0H,反应生成 曲金刚胺
参考文献:Compounds Containing An Alicyclie Structure And Anti-Tumor Application
标题:Compounds Containing An Alicyclie Structure And Anti-Tumor Application
摘要:这项发明涉及含有金刚烷基团或其类似物的新化合物的抗肿瘤活性.该发明还涉及利用这种含有金刚烷基团的s,P,T结构的化合物与立体异构体,互变异构体,前药,药用盐,复杂盐或溶剂化物的结合来治疗抗肿瘤和其他疾病的药物应用,这些抗肿瘤剂具有以下一般公式:

专利信息

专利号:US-2016185745-A1
优先权日:2013-08-07
标题:Analogs of vinaxanthone and xanthofulvin, methods of synthesis, and methods of treatments thereof
发明人：SIEGEL DIONICIO; CHIN MATTHEW; ELIASEN ANDERS; AXELROD ABRAM
权利人:UNIV TEXAS
摘要:The present invention relates generally to methods of synthesis of vinaxanthone and xanthofulvin, novel analogs, and methods of use thereof.

专利号:US-11649285-B2
优先权日:2016-08-03
标题 :Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
发明人：KALABOKIS VASSILIOS; WANG JINGHUA; WU GUOPING; BAZAN JOSE FERNANDO; VALLEY CHRISTOPHER CARLIN
权利人:BIO TECHNE CORP
摘要:The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

专利号:US-5110929-A
优先权日:1986-08-07
标题 :Process for the preparation of N-alkylated quaternary nitrogen containing aromatic heterocycles
发明人：PARADIES HENRICH H
权利人:MEDICE CHAM PHARM FABRIK PUTTE
摘要:The synthesis of 4-, 4-(1,1)-and 3,5-substituted N-alkyl-pyridinium salts as well as of 2-carboxamide substituted N(1,4)diazinium compounds are described. The N-surfactants obtained have a small critical micelle concentration (CMC) of 10-5 -10-7 Mol/Liter. These surfactants produce micells of different size and form depending on the nature of the anions. 4-(1,1)-substituted and 3,5-substituted N-alkyl-pyridinium components are capable of forming vesicles in equeous solutions of different forms and sizes. The N-surfactants synthesized can be used as pharmaceuticals.

专利号:US-9522932-B2
优先权日:2004-03-04
标 题 :Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
发明人：HERDEWIJN PIET; PANNECOUQUE CHRISTOPHE; WU TONGFEI; DE CLERCQ ERIK
权利人:LEUVEN K U RES & DEV
摘要:The invention is directed to a process for the preparation of substituted threonolactone and substituted threose compounds which are intermediates in the synthesis of phosphonate nucleosides being useful antiviral agents.

专利号:US-12295961-B2
优先权日:2009-12-31
标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
发明人：DHINGRA OM
权利人:MARIUS PHARMACEUTICALS INC
摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

专利号:US-10370455-B2
优先权日:2014-12-05
标题 :Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists
发明人：MOLLOY MICHAEL; GUO YALIN; ROTHSTEIN JAY; ROSENZWEIG MICHAEL
权利人:IMMUNEXT INC
摘要:The receptor for VISTA is identified (VSIG8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG8 and/or VISTA and/or the VSIG8/VISTA binding interaction. These antagonists may be used to suppress VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.